Health New Vaccine That Targets 90% of Cancers Shows Promising Results in Human Safety Trial

[tom_mai78101]

ImMucin, a vaccine that targets a molecule present in 90 percent of all cancers, has been tested on humans for the first time, according to researchers who found that all the blood cancer patients tested in the trial had greater immunity to the disease after receiving the drug.

Results have yet to be formally published, but if the findings are confirmed in future trials then the vaccine could be on the market in six years.

The clinical trial was conducted at the Hadassah Medical Centre in Jerusalem and consisted of ten patients with multiple myeloma, a type of blood cancer that affects plasma cells in bone marrow, have now received the vaccine.

Researchers from the drug maker Vaxil Biotheraputics and Tel Aviv University said that seven of the patients who have finished treatment all had significantly greater immunity against cancer cells compared to before they were given the vaccine, and three of the patients in the study are now free of the condition.

New Vaccine That Targets 90% of Cancers Shows Promising Results in Human Safety Trials

ImMucin, a vaccine that targets a molecule present in 90 percent of all cancers, has been tested on humans for the first time, according to researchers who found that all the blood cancer patients tested in the trial had greater immunity to the disease after receiving the drug.

www.medicaldaily.com

Please do not pronounce ImMucin as "I'm moosing."

 

[Wummi]

3 words: I Am Legend

 

[Sajin]

3 words: I Am Legend

Alternative end or beginning?

 

[Wummi]

Of course, the beginning!

 

[The Helper]

10 years later and nothing....

 

[tom_mai78101]

Probably because I wasn't following this.

Vaxil's Lead Product ImMucin has Been Granted an Orphan Drug Designation by the FDA for the Treatment of Multiple Myeloma

Vaxil Bio, (TASE: VAXL) a company specializing in the development of immunotherapy-based drugs, reports today that its lead product, ImMucin, has been granted an "orphan drug" designation by the US Food and Drug Administration (FDA), for the treatment of multiple myeloma (MM).

ImMucin is an immunotherapeutic treatment which educates the MM patient's immune system, particularly T-cells and antibodies, to attack MM cancer cells via a specific domain, termed signal peptide, of the tumor marker MUC1. This domain bears significant advantages as an immunotherapeutic modality. Immunotherapy as a cancer treatment modality has become an important field of medicine during the last two years. It has been the subject of great interest, as drugs that utilize the mechanisms of the immune system have been shown to produce results with far-reaching consequences, and have turned out to be "game changers" in the treatment of this disease.

"Orphan drug" designation is granted by the FDA in order to promote the clinical development of drugs and treatments with significant treatment potential against rare (fewer than 200,000 people in the US) life-threatening diseases. "Orphan drug" designation grants the exclusivity to market in the US for 7 years from the moment the approval is provided.

Dr. Lior Carmon, CEO and founder of Vaxil: "Despite notable recent advances in the treatment of MM, there are still no options resulting in full recovery from the disease. This is why there is a need for drugs that can delay the recurrence of the disease. ImMucin is intended to meet this need in MM patients with "minimal residual disease", turning their cancer into a chronic manageable disease. In light of the clinical results achieved thus far with ImMucin, manifested by a strong diversified immune response, we believe that ImMucin has great therapeutic and economic potential.

Vaxil's Lead Product ImMucin has Been Granted an Orphan Drug Designation by the FDA for the Treatment of Multiple Myeloma

/PRNewswire/ -- Vaxil Bio, (TASE: VAXL) a company specializing in the development of immunotherapy-based drugs, reports today that its lead product, ImMucin,...

www.prnewswire.com

Note the boldfaced text above.

 

[The Helper]

I see it only works for certain types of cancers

"Orphan drug" designation is granted by the FDA in order to promote the clinical development of drugs and treatments with significant treatment potential against rare (fewer than 200,000 people in the US) life-threatening diseases. "Orphan drug" designation grants the exclusivity to market in the US for 7 years from the moment the approval is provided.